In conclusion, we constructed a ROS/GSH dual sensitive drug delivery system (CUR/miR155@DssD-Hb NPs) to co-delivery CUR and miR155 for activating the robust and long-lasting anti-tumor immune response. This evidence concerns the gene GSTM1 and neoplasm.